RE:RE:it's a buy today for meIf you look at a Linc presentation on the different covered stents then you will find that Inspiremd has a very unique offering with ultra-thin PET materials since most are PTFE and are better suited to different applications. This may be partly why NSPR testing is compared to surgical stents in their programs rather than approved covered balloon stents.
Look for a takeover as NSPR gets closer to FDA approval, and a substantially higher SP if preliminary positive results come from the US program. The technology has to be worth $300M or more for a bigger player who wants an approved product. Current sales are not getting the attention from the potential suitors ... hopefully the next Q results will show increased sales to help stem the cash drain.